title: The rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17α-hydroxyprogesterone caproate.
abstract: We compared the rates of abnormal 1-hour glucose challenge tests (GCT) and gestational diabetes (GDM) between women receiving 17α-hydroxyprogesterone caproate (17-P) and women who did not receive 17-P to determine if the effect varies based on the number of doses received or in a group of high-risk obese women. We performed a secondary analysis of a prospective cohort study where women with a history of a previous preterm delivery in the antecedent pregnancy followed at a high-risk clinic were offered 17-P. GCT was performed after the initiation of 17-P, and doses given prior to testing were recorded. Rates of abnormal GCT and GDM were compared between those receiving 17-P ( N = 67) and controls ( N = 140). Mean glucose values (112.4 versus 111.3,  P = 0.8), rate of abnormal GCT (23.9% versus 20%, adjusted odds ratio 1.45, 95% confidence interval 0.7 to 3.0), and rate of GDM (6% versus 8.6%, adjusted odds ratio 1.21, 95% confidence interval 0.3 to 4.5) were similar between groups. In this prospective study, 17-P administration to women at risk of recurrent preterm delivery did not significantly affect glucose tolerance.
authors.affiliation: Division of Maternal-Fetal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, 45267-0526, USA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Wolfe
authors.forename: Christine
authors.initials: C
authors.lastname: Dearmond
authors.forename: Helen
authors.initials: H
authors.lastname: How
authors.forename: Zsakeba T
authors.initials: ZT
authors.lastname: Henderson
authors.forename: Baha
authors.initials: B
authors.lastname: Sibai
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D000328:Adult; D001786:Blood Glucose; D016640:Diabetes, Gestational / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D005260:Female; D018149:Glucose Intolerance / Q000139:chemically induced*; D005951:Glucose Tolerance Test; D006801:Humans; D006908:Hydroxyprogesterones / Q000009:adverse effects* / Q000627:therapeutic use; D016015:Logistic Models; D009765:Obesity / Q000150:complications; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control; D011372:Progestins / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D055502:Secondary Prevention; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D006908:Hydroxyprogesterones; D011372:Progestins; D000077713:17 alpha-Hydroxyprogesterone Caproate